Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.

Bakker-Woudenberg IA, ten Kate MT, Guo L, Working P, Mouton JW.

Antimicrob Agents Chemother. 2001 May;45(5):1487-92.

2.

Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.

Bakker-Woudenberg IA, ten Kate MT, Guo L, Working P, Mouton JW.

Antimicrob Agents Chemother. 2002 Aug;46(8):2575-81.

3.
4.
5.

Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue.

Bakker-Woudenberg IA, Lokerse AF, ten Kate MT, Mouton JW, Woodle MC, Storm G.

J Infect Dis. 1993 Jul;168(1):164-71.

PMID:
8515105
6.

Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models.

Schiffelers RM, Storm G, Bakker-Woudenberg IA.

Int J Pharm. 2001 Feb 19;214(1-2):103-5.

PMID:
11282246
7.

Impact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel MF.

Eur J Clin Microbiol Infect Dis. 1991 Dec;10(12):1019-25.

PMID:
1839380
8.

Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia.

Ellbogen MH, Olsen KM, Gentry-Nielsen MJ, Preheim LC.

J Antimicrob Chemother. 2003 Jan;51(1):83-91.

PMID:
12493791
9.

Influence of dose frequency on the therapeutic efficacies of ciprofloxacin and ceftazidime in experimental Klebsiella pneumoniae pneumonia and septicemia in relation to their bactericidal activities in vitro.

Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel MF.

Pharm Weekbl Sci. 1987 Dec 11;9 Suppl:S33-40.

PMID:
3325928
10.

Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.

Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel MF.

Antimicrob Agents Chemother. 1987 Nov;31(11):1809-15.

11.

Long-circulating sterically stabilized liposomes in the treatment of infections.

Bakker-Woudenberg IA, Schiffelers RM, Storm G, Becker MJ, Guo L.

Methods Enzymol. 2005;391:228-60.

PMID:
15721385
12.

Evaluation of trovafloxacin in the treatment of Klebsiella pneumoniae lung infection in tumour-bearing mice.

Thadepalli H, Reddy U, Chuah SK, Hanna N, Rana G, Gollapudi S.

J Antimicrob Chemother. 2000 Jan;45(1):69-75.

PMID:
10629015
13.
14.

Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.

Rodríguez-Martínez JM, Pichardo C, García I, Pachón-Ibañez ME, Docobo-Pérez F, Pascual A, Pachón J, Martínez-Martínez L.

Clin Microbiol Infect. 2008 Jul;14(7):691-7. doi: 10.1111/j.1469-0691.2008.02020.x.

17.

Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel BM.

Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):878-87.

PMID:
2512132
18.

Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats.

Join-Lambert OF, Michéa-Hamzehpour M, Köhler T, Chau F, Faurisson F, Dautrey S, Vissuzaine C, Carbon C, Pechère J.

Antimicrob Agents Chemother. 2001 Feb;45(2):571-6.

19.

In vitro and in vivo activities of ciprofloxacin and levofloxacin against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.

Szabó D, Máthé A, Lengyel J, Anderlik P, Rókusz L, Rozgonyi F.

Curr Med Chem. 2002 Feb;9(4):437-42.

PMID:
11945119

Supplemental Content

Support Center